Orthocell (ASX: OCC) is an Australian-listed company in the Healthcare sector with a market capitalisation of $167.7M and the 707th-largest security on the ASX by market capitalisation. The OCC share price is $0.755, down 1.31% today and down 37.08% over the past 12 months. Shares have traded between $0.70 and $1.60 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Orthocell reported revenue of $5.4M and a net loss of $5.2M.
Charts
$0.77
24H Range
$0.745
$0.775
52-Week Range
$0.70
$1.60
About Orthocell Limited
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
The OCC share price is $0.755, down 1.31% for the day, based on the latest available ASX market data.
What is Orthocell's market capitalisation?
Orthocell has a market capitalisation of $167.7M, making it the 707th-largest security listed on the ASX.
Does Orthocell pay a dividend?
OCC does not currently have a dividend on record. Some companies, particularly those reinvesting in growth or not yet profitable, do not pay dividends.
Is Orthocell profitable?
In its most recent reported period (ending 31 Dec 2025), OCC reported revenue of $5.4M and a net loss of $5.2M.
How many OCC shares are on issue?
Orthocell has approximately 222,078,852 shares on issue, based on its market capitalisation of $167.7M and current share price.
What sector is Orthocell in?
Orthocell is classified in the Healthcare sector, within the Biotechnology industry on the ASX.
When did Orthocell list on the ASX?
Orthocell listed on the Australian Securities Exchange on 12 Aug 2014.
OCC is held by 1 ASX-listed fund tracked on this site. The largest allocation is in Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) at 0.00% of its portfolio.
